Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

SHA:600329 Revenue

Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of 963.22M CNY in the quarter ending September 30, 2026, a decrease of -5.51%. This brings the company's total for the last twelve months to 4.67B, down -13.05% year-over-year. In the year 2025, Tianjin Pharmaceutical Da Ren Tang Group Corporation had annual revenue of 4.92B, down -32.70%. That makes Tianjin Pharmaceutical Da Ren Tang Group Corporation the 9,329th largest company in the world by revenue and 1,492nd in China.

• Revenue (ttm): 4.67B
• Revenue Growth: -13.05%
• P/S Ratio: 5.67
• Revenue / Employee: 1.20M
• Employees: 3,890
• Market Cap: 26.45B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Chinese Patent Medicine 4.46B 90.7%
• Others 366.23M 7.4%
• Western Medicine 89.94M 1.8%

By Geography

Chart

• China 4.87B 99.0%
• Overseas 47.80M 1.0%

Fiscal year ended Dec 31, 2025 See the full SHA:600329 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.92B	-2.39B	-32.70%
Dec 31, 2024	7.31B	-915.58M	-11.14%
Dec 31, 2023	8.22B	-26.94M	-0.33%
Dec 31, 2022	8.25B	1.34B	19.42%
Dec 31, 2021	6.91B	303.89M	4.60%

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error